RS61611B1 - Upotreba kompozicije koja sadrži benzoat kod poremećaja ciklusa uree i neurodegenerativnih poremećaja - Google Patents
Upotreba kompozicije koja sadrži benzoat kod poremećaja ciklusa uree i neurodegenerativnih poremećajaInfo
- Publication number
- RS61611B1 RS61611B1 RS20210230A RSP20210230A RS61611B1 RS 61611 B1 RS61611 B1 RS 61611B1 RS 20210230 A RS20210230 A RS 20210230A RS P20210230 A RSP20210230 A RS P20210230A RS 61611 B1 RS61611 B1 RS 61611B1
- Authority
- RS
- Serbia
- Prior art keywords
- mice
- gtb
- eae
- pharmaceutical composition
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461928622P | 2014-01-17 | 2014-01-17 | |
| PCT/US2015/011798 WO2015109215A1 (en) | 2014-01-17 | 2015-01-16 | The use of a benzoate containing composition in urea cycle disorders and neurodegenerativre disordrs |
| EP15737329.1A EP3094616B1 (en) | 2014-01-17 | 2015-01-16 | The use of glyceryl tribenzoate containing composition in neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS61611B1 true RS61611B1 (sr) | 2021-04-29 |
Family
ID=53543490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20210230A RS61611B1 (sr) | 2014-01-17 | 2015-01-16 | Upotreba kompozicije koja sadrži benzoat kod poremećaja ciklusa uree i neurodegenerativnih poremećaja |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9968582B2 (enExample) |
| EP (1) | EP3094616B1 (enExample) |
| JP (2) | JP6836905B2 (enExample) |
| CA (1) | CA2936548C (enExample) |
| CY (1) | CY1124115T1 (enExample) |
| DK (1) | DK3094616T3 (enExample) |
| ES (1) | ES2853974T3 (enExample) |
| HR (1) | HRP20210361T1 (enExample) |
| HU (1) | HUE053671T2 (enExample) |
| LT (1) | LT3094616T (enExample) |
| PL (1) | PL3094616T3 (enExample) |
| PT (1) | PT3094616T (enExample) |
| RS (1) | RS61611B1 (enExample) |
| SI (1) | SI3094616T1 (enExample) |
| SM (1) | SMT202100074T1 (enExample) |
| WO (1) | WO2015109215A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11304923B2 (en) | 2017-10-06 | 2022-04-19 | Rush University Medical Center | Use of a benzoate containing composition to treat glycine encephalopathy |
| US11826326B2 (en) * | 2017-11-22 | 2023-11-28 | Excelsior Pharmatech Labs | Benzoic acid or a salt and derivative thereof for use in preventing or treating depression |
| AU2020229316A1 (en) * | 2019-02-25 | 2021-09-16 | Rush University Medical Center | Compositions including cinnamic acid and methods of use thereof |
| JP2022541021A (ja) * | 2019-07-16 | 2022-09-21 | ラッシュ・ユニバーシティ・メディカル・センター | 神経変性障害を治療するためのベンゾエート含有組成物の使用 |
| WO2022093922A1 (en) * | 2020-10-28 | 2022-05-05 | Rush University Medical Center | Use of a cinnamein composition for the treatment of glycine encephalopathy and urea cycle disorders |
| EP4262781A4 (en) * | 2020-12-16 | 2025-02-12 | Rush University Medical Center | Administration of glycerol tribenzoate and glycerol phenylbutyrate for treatment of neurodegenerative and urea cycle disorders |
| CA3241282A1 (en) * | 2021-12-16 | 2023-06-22 | Kalipada PAHAN | Benzoic acid salts for treatment of nervous system injuries and disorders |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4284647A (en) * | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| WO2008083226A2 (en) | 2006-12-28 | 2008-07-10 | Navinta Llc | Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate |
-
2015
- 2015-01-16 HU HUE15737329A patent/HUE053671T2/hu unknown
- 2015-01-16 SI SI201531511T patent/SI3094616T1/sl unknown
- 2015-01-16 SM SM20210074T patent/SMT202100074T1/it unknown
- 2015-01-16 JP JP2016565117A patent/JP6836905B2/ja active Active
- 2015-01-16 ES ES15737329T patent/ES2853974T3/es active Active
- 2015-01-16 CA CA2936548A patent/CA2936548C/en active Active
- 2015-01-16 DK DK15737329.1T patent/DK3094616T3/da active
- 2015-01-16 PL PL15737329T patent/PL3094616T3/pl unknown
- 2015-01-16 US US15/110,702 patent/US9968582B2/en active Active
- 2015-01-16 EP EP15737329.1A patent/EP3094616B1/en active Active
- 2015-01-16 WO PCT/US2015/011798 patent/WO2015109215A1/en not_active Ceased
- 2015-01-16 HR HRP20210361TT patent/HRP20210361T1/hr unknown
- 2015-01-16 RS RS20210230A patent/RS61611B1/sr unknown
- 2015-01-16 PT PT157373291T patent/PT3094616T/pt unknown
- 2015-01-16 LT LTEP15737329.1T patent/LT3094616T/lt unknown
-
2019
- 2019-10-18 JP JP2019191224A patent/JP2020037558A/ja active Pending
-
2021
- 2021-03-09 CY CY20211100204T patent/CY1124115T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1124115T1 (el) | 2022-05-27 |
| WO2015109215A1 (en) | 2015-07-23 |
| CA2936548C (en) | 2022-08-30 |
| EP3094616B1 (en) | 2020-12-23 |
| JP6836905B2 (ja) | 2021-03-03 |
| US9968582B2 (en) | 2018-05-15 |
| EP3094616A4 (en) | 2017-08-23 |
| JP2020037558A (ja) | 2020-03-12 |
| PL3094616T3 (pl) | 2021-05-31 |
| US20160331714A1 (en) | 2016-11-17 |
| JP2017505811A (ja) | 2017-02-23 |
| SMT202100074T1 (it) | 2021-05-07 |
| HRP20210361T1 (hr) | 2021-04-16 |
| DK3094616T3 (da) | 2021-02-15 |
| LT3094616T (lt) | 2021-04-12 |
| HUE053671T2 (hu) | 2021-07-28 |
| ES2853974T3 (es) | 2021-09-20 |
| CA2936548A1 (en) | 2015-07-23 |
| EP3094616A1 (en) | 2016-11-23 |
| PT3094616T (pt) | 2021-03-03 |
| SI3094616T1 (sl) | 2021-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS61611B1 (sr) | Upotreba kompozicije koja sadrži benzoat kod poremećaja ciklusa uree i neurodegenerativnih poremećaja | |
| JP5712207B2 (ja) | 脳疾患及び状態の予防及び治療のための組成物及び方法 | |
| EP3528835B1 (fr) | Compositions antivirales pour le traitement des infections liees aux coronavirus | |
| TWI574694B (zh) | 一種使用包含前花青素聚合物秘魯巴豆(croton lechleri) 之萃取物於製備用於治療腹瀉型腸躁症的藥物之用途 | |
| AU2014260468A1 (en) | Sobetirome in the treatment of myelination diseases | |
| MX2012007778A (es) | Diazoxido para su uso en el tratamiento o prevencion de una enfermedad desmielinizante autoinmunitaria del sistema nervioso central (snc). | |
| US20120237482A1 (en) | Methods for treatment of neurological disorders by modulation of microglial activation | |
| RU2336870C2 (ru) | Применение l-бутилфталида для изготовления лекарственного средства для профилактики и лечения церебрального инфаркта | |
| US11207331B2 (en) | Agents, compositions and methods for enhancing neurological function | |
| JP2020502278A (ja) | 青黛抽出物又はその分画物を有効成分として含む炎症性腸疾患の予防又は治療のための医薬組成物 | |
| JP2022521233A (ja) | 桂皮酸を含む組成物及びその使用方法 | |
| JP6529634B1 (ja) | アミロイドβ分解排出促進剤 | |
| CN104379142B (zh) | 用于免疫调节的拉多替吉治疗 | |
| Bachert et al. | Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjunctivitis | |
| CN106361738A (zh) | 治疗、预防脑白质损伤的医药组合物及其医药用途 | |
| AN et al. | Exploring the potential of bioactive compounds as interventions for dementia: current insights and future directions | |
| KR20200065012A (ko) | 글리신 뇌병증 치료를 위한 벤조에이트 함유 조성물의 사용 | |
| WO2005002568A1 (fr) | Utilisation de 1-n-butylphtalide pour la prevention ou les traitements de la demence | |
| JP5634062B2 (ja) | 脳機能改善用組成物および脳機能を改善する方法 | |
| CN104173361A (zh) | 宝霍苷i在制备防治阿尔茨海默病药物中的用途 | |
| CN104411308A (zh) | 通过给予某些合成化合物治疗阿尔茨海默病的方法 | |
| RU2805061C2 (ru) | Лечение демиелинизирующих заболеваний | |
| US20230201134A1 (en) | Compositions for the management of demyelinating disorders | |
| CN113057977A (zh) | 一种改善学习记忆的片剂及其制备方法 | |
| EA049313B1 (ru) | Применение 2-(имидазол-4-ил)этанамид пентандиовой-1,5 кислоты для лечения covid-19 |